Skip to main content
OpenTrials
Completed

NCT Number: NCT02083783

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States

Loading trial locations.

About this study

A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multicenter, laboratory classroom study. After Screening and Baseline evaluations, eligible subjects are enrolled in the study and entered the open-label phase, dose-optimization phase. TRI102 is taken once daily and subjects undergo dose optimization activities for 5 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition

Exclusion criteria

  • Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD

Treatment and study plan

TRI102

Drug

formulation containing active moiety (amphetamine)

Other names: amphetamine extended-release oral suspension

Placebo

Other

formulation without active moiety

Primary outcomes

  1. SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale)

    Time frame: Absolute change from baseline in SKAMP-C score from baseline to 4 hours after dose

    Change from baseline in SKAMP-Combined Scores measured approximately 4 hours after dose (active or placebo). The SKAMP-Combined score is obtained by summing 13 assessment items, where each item is rated on a 7-point scale (0 = normal to 6 = maximal impairment). This gives an overall (combined) SKAMP Score of 0= normal to 78 which indicates maximal impairment. The endpoint is assessed as a change from baseline in the overall score on the 78-point scale.

Secondary outcomes

  1. PERMP (Permanent Product Measure of Performance).

    Time frame: Absolute change from baseline in PERMP questions answered correctly, measured from baseline to 4 hours postdose.

    The PERMP is a math test that measures effortful performance without a learning curve (Wigal and Wigal 2006). The test determines the number of problems attempted and the number of problems correctly answered. In this study, the primary efficacy measure was a PERMP evaluation done 4 hours after taking study medication, a time selected a priori to coincide with the known pharmacodynamic effects based on prior research and to minimize the impact of repeated measures on adjustment of multiplicity (Wigal et al. 1998; Pelham et al. 2001). The PERMP consists of 400 math questions and each are scored. PERMP scores are expressed as the number of questions correct. Predose PERMP Tests are compared with post-dose PERMP scores at prespecfied timepoints.

Sponsors and collaborators

Lead sponsor

Tris Pharma, Inc.

Industry

Registry information

Official study title

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Mar 11, 2014
Registry last updated
Aug 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.